Skip to main content
Guobang Pharma Ltd. logo

Guobang Pharma Ltd. — Investor Relations & Filings

Ticker · 605507 ISIN · CNE100004NS2 LEI · 300300PS6T4W4PGYPM51 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 510 across all filing types
Latest filing 2025-04-22 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 605507

About Guobang Pharma Ltd.

https://www.gbgcn.com

Guobang Pharma Ltd. specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage forms. The company operates across two primary sectors: human health and animal health. Its product portfolio includes a wide range of anti-infectives, such as macrolides and quinolones, as well as cardiovascular medications and veterinary drugs like florfenicol. Guobang Pharma maintains a comprehensive industrial chain, leveraging large-scale production facilities and advanced chemical synthesis technologies to serve global markets. The organization focuses on providing integrated solutions for pharmaceutical raw materials, emphasizing quality control and regulatory compliance to meet international standards.

Recent filings

Filing Released Lang Actions
国邦医药关于股份回购进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Guobang Pharmaceutical Group Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and the purpose of the repurchase (employee stock ownership plan or equity incentive). The document references previous announcements about the repurchase plan and provides updates on the repurchase progress. It does not contain financial statements or detailed financial analysis but is focused on the company's share buyback activity. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is short and is a progress update, not a full report or regulatory certification, so it is not RNS or RPA.
2025-04-22 Chinese
国邦医药关于全资子公司参与设立股权投资基金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Guobang Pharmaceutical Group Co., Ltd. regarding its wholly-owned subsidiary's participation in establishing an equity investment fund. It details the investment amount, partners, fund structure, management fees, profit distribution, and risk warnings. The document is a formal disclosure about a capital investment transaction, not a financial report, earnings release, or management discussion. It does not contain financial statements or quarterly/yearly results. It is not a regulatory certification or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it informs about a new investment and capital allocation by the company.
2025-04-21 Chinese
国邦医药2025年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2025 First Quarter Report" of Guobang Pharmaceutical Group Co., Ltd. It contains detailed financial data including balance sheets, profit and loss statements, and cash flow statements for the first quarter of 2025. The report explicitly states it is unaudited and covers the period January to March 2025, which is a period shorter than a full fiscal year. The presence of comprehensive financial statements and analysis for a quarter indicates this is an Interim / Quarterly Report. The document length is over 12,000 characters and contains substantive financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2025-04-15 Chinese
国邦医药关于以集中竞价交易方式首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the company's first share repurchase through centralized bidding. It details the repurchase plan, progress, and compliance with relevant regulations. The content focuses on the company's buyback of its own shares, including quantities, prices, and purposes such as employee stock ownership plans or equity incentives. There is no financial report, earnings data, or management discussion. The document is a formal announcement of a share repurchase transaction, fitting the category of Transaction in Own Shares (POS). The document length is short and it is not a report publication or certification, so it is not RPA or RNS.
2025-04-07 Chinese
国邦医药关于股份回购进展公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from Guobang Pharmaceutical Group Co., Ltd. regarding the progress of its share repurchase plan. It details the repurchase scheme, including the amount, purpose, and progress to date, with no actual financial statements or earnings data presented. The document is short (1129 characters) and focuses on the update of the share buyback activity, consistent with a Transaction in Own Shares (POS) filing. It is not an annual or interim report, nor a regulatory filing or announcement of a report publication. Therefore, the appropriate classification is POS.
2025-04-01 Chinese
国邦医药关于公司及子公司开展外汇套期保值业务的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Guobang Pharmaceutical Group Co., Ltd. regarding the company's and its subsidiaries' plan to conduct foreign exchange hedging business. It details the purpose, transaction types, amounts, risk analysis, and internal controls related to the hedging activities. The document includes information about a board meeting approving the hedging business but does not contain financial statements or detailed financial results. It is a regulatory announcement about a capital/financial activity (foreign exchange hedging) rather than a full financial report or earnings release. The document length is about 2558 characters, which is relatively short and focused on a specific financing-related activity. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-03-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.